Sign in
Taking peoplePhase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Key facts

Who runs it
National University of Singapore
Where
Australia, China, Lebanon, Malaysia, Qatar, Saudi Arabia, Singapore, South Africa, Spain, Thailand, Türkiye, and United Arab Emirates41 sites in 12 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
600 people, planned
Started
21 Apr 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 14 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Colistin/Polymyxin B + Sulbactam
  • Colistin/Polymyxin B + Tigecycline/Eravacycline
  • Colistin/Polymyxin B + Meropenem
  • Ceftazidime-avibactam + Sulbactam
  • Ceftazidime-avibactam + Fosfomycin
  • Ceftazidime-avibactam
  • Ceftazidime-avibactam + Aztreonam
  • Ceftazidime-avibactam + Colistin/Polymyxin B
  • High-dose meropenem
  • Meropenem + Fosfomycin
  • Meropenem-vaborbactam
  • Cefiderocol
  • Ceftolozane-tazobactam
  • Ceftolozane-tazobactam + Meropenem
Record updated
4 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • A: Bloodstream infections
  • Suitable for at least 2 antibiotic regimens in the site randomisation list
  • Growth of Gram-negative bacilli identified from blood culture(s)
  • Receiving or planning to receive intravenous antibiotics
  • Expected time from blood culture sampling to randomisation is ≤ 96 hours; OR; B: Ventilator-associated pneumonia / hospital-acquired pneumonia a) Suitable for at least 2 antibiotic regimens in the site randomisation list b) Infection syndrome definitions\^( (US Centers for Disease Control and Prevention National Healthcare Safety Network)3: i) At least one of the following:
  • temperature > 38 °C
  • white blood cell count ≥ 12,000 cells/mm3 (12 x 109/L, 12 x 103/µL) or ≤ 4,000 cells/mm3 (4 x 109/L, 4 x 103/µL)
  • altered mental status with no other causes in > 70 years old; AND ii) Two or more chest imaging tests demonstrating at least one of the following:
  • new and progressive OR progressive and persistent infiltrate 2) new and persistent OR progressive and persistent consolidation 3) new and persistent OR progressive and persistent cavitation; AND iii) At least two of the following:
  • new onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased in suctioning requirements
  • new onset or worsening tachypnoea or dyspnoea
  • rales or bronchial breath sounds
  • worsening gas exchange defined by oxygen desaturations (e.g., PaO2/FiO2 < 240), increased oxygen requirements or increased ventilation demand; Hospital admission > 48 hours d) Predominant growth of Gram-negative bacilli identified from respiratory tract specimen(s)*; e) Receiving or planning to receive intravenous antibiotics f) Expected time from respiratory culture sampling to randomisation is ≤ 96 hours; AND; C: CR-GNB antibiotic backbone domain; Gram-negative bacilli belonging to Acinetobacter baumannii-calcoaceticus complex, Pseudomonas aeruginosa or Enterobacterales b) Carbapenem resistance in isolate detected - i) Phenotypically via conventional microbiology testing: meropenem / imipenem / ertapenem resistance; OR ii) Genotypically via PCR or next generation sequencing: presence of genes associated with carbapenemase production (eg. blaNDM, blaKPC, blaIMP, blaIMI, blaVIM, blaOXA-48-like)

Who cannot take part

  • Polymicrobial bloodstream infection
  • Treating team deems enrolment in the study is not in the best interest of the patient
  • Patient is on end-of-life care
  • Patient is incarcerated in a correctional facility
  • Participation in any interventional study activities outlined in the TREAT-GNB study within the last 90 days
  • Pregnant women and children; OR

This trial has no sites in United States.

It has sites in 12 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria.

Read full original descriptionShow less

In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.

The 14 groups in the trial

  • Colistin/Polymyxin B + SulbactamExisting treatment, for comparison
  • Colistin/Polymyxin B + Tigecycline/EravacyclineExisting treatment, for comparison
  • Colistin/Polymyxin B + MeropenemExisting treatment, for comparison
  • Ceftazidime-avibactam + SulbactamExisting treatment, for comparison
  • Ceftazidime-avibactam + FosfomycinExisting treatment, for comparison
  • Ceftazidime-avibactamExisting treatment, for comparison
  • Ceftazidime-avibactam + AztreonamExisting treatment, for comparison
  • Ceftazidime-avibactam + Colistin/Polymyxin BExisting treatment, for comparison
  • High-dose meropenemExisting treatment, for comparison
  • Meropenem + FosfomycinExisting treatment, for comparison
  • Meropenem-vaborbactamExisting treatment, for comparison
  • CefiderocolExisting treatment, for comparison
  • Ceftolozane-tazobactamExisting treatment, for comparison
  • Ceftolozane-tazobactam + MeropenemExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
TREAT-GNB [CR-GNB]
Record updated
4 June 2025